Related Experiment Video
Updated: Jul 9, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Cetuximab in non-small cell lung cancer
Foluso O Ademuyiwa1, Nasser Hanna
1Indiana University School of Medicine, Division of Hematology/Oncology, 535 Barnhill Drive, RT 473, Indianapolis, IN 46202, USA. fademuyi@iupui.edu
Abstract:
Advanced non-small cell lung carcinoma (NSCLC) remains a challenge to treat due to its high local and systemic recurrence. The overall survival remains poor despite the approval of several new chemotherapeutic agents in the management of advanced NSCLC. Overexpression or mutations in the EGFR have been shown to be associated with a significant percentage of NSCLC. The development of targeted agents, such as cetuximab, against the EGFR is therefore a rational objective. Several preclinical and clinical studies suggest that cetuximab is active against NSCLC. This paper reviews the application of cetuximab in NSCLC.
